Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer By Ogkologos - January 14, 2025 865 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INSEMA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with... June 13, 2024 What to Know About Cancer Care and Research for People 65+:... February 28, 2023 FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer November 20, 2023 How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective June 28, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Cancer Patients May Soon Be Able to Get an Entire Course... ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... Coronavirus reports – Part 10: “I didn’t see my mum before...
